Orchid Pharma Limited (ORCHPHARMA) — Strategic Asset Allocation Index

Latest as of September 2022: 99.0%

Orchid Pharma Limited (ORCHPHARMA) has a Strategic Asset Allocation Index of 99.0% as of September 2022. Strategic assets (PP&E of Rs6.16 Billion plus long-term investments of Rs-) total Rs6.16 Billion, measured against net assets of Rs6.22 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

99.0%
Strategic Assets / Net Assets

Strategic Assets

Rs6.16 Billion
PP&E + LT Investments

PP&E

Rs6.16 Billion
INR

Net Assets

Rs6.22 Billion
INR

Orchid Pharma Limited Strategic Asset Allocation Index (2020–2022)

This chart shows how Orchid Pharma Limited's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of September 2022, the index stands at 99.0%, representing strategic assets of Rs6.16 Billion against net assets of Rs6.22 Billion INR. Explore cash efficiency ratio of Orchid Pharma Limited to assess how effectively this company generates cash.

Annual Strategic Asset Allocation Index for Orchid Pharma Limited (2020–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for Orchid Pharma Limited from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Orchid Pharma Limited (ORCHPHARMA) total market value.

Year SAAI Strategic Assets (INR) PP&E LT Investments Net Assets Change (pp)
2022 91.6% Rs5.93 Billion Rs5.93 Billion Rs- Rs6.47 Billion ▼ -12.1 pp
2021 103.8% Rs6.78 Billion Rs6.78 Billion Rs- Rs6.53 Billion ▼ -8.3 pp
2020 112.1% Rs8.59 Billion Rs8.59 Billion Rs- Rs7.66 Billion
pp = percentage points